<DOC>
	<DOCNO>NCT00651014</DOCNO>
	<brief_summary>The study design ass whether 6 week co-administration ezetimibe simvastatin effective simvastatin monotherapy allow patient CHD risk stratum NCEP III guideline achieve LDL-C target goal &lt; =3.0 mmol/L . As study conduct Canada , target LDL-C goal patient CHD , type II diabetic patient &gt; 30 year old CHD , &lt; 2.5 mmol/L .</brief_summary>
	<brief_title>Ezetimibe Plus Simvastatin Versus Simvastatin Patients With Hypercholesterolemia Coronary Risk Factors ( P03405 )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>&gt; =18 year age treat simvastatin 10 mg 20 mg least 6 week LDLC level &gt; 2.5 mmol/L &lt; =4.20 mmol/L ( 97 mg/dL 160 mg/dL ) Visit 1. history coronary heart disease ( type II diabetic patient &gt; 30 year old CHD ) triglycerides &lt; = 4.00 mmol/L drawn , liver transaminase ( ALT , AST ) &lt; =50 % upper limit normal Visit 2 , active liver disease , and/or creatine kinase ( CK ) &lt; =50 % upper limit normal subject Body Mass Index &gt; =35 kg/sqm Visit 1 alcohol consumption &gt; 14 drink per week pregnant lactating treat investigational drug within 30 day prior Visit 1 previously treat ezetimibe participate clinical study ezetimibe condition situation , opinion investigator , might pose risk patient interfere participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>